Cargando…

Simulation work in adaptive dose-finding designs to identify dose-intervals that achieve targets in multiple endpoints

Detalles Bibliográficos
Autores principales:	Howlett, James, Bond, Simon, Mander, Adrian, Todd, John, Wicker, Linda, Waldron-Lynch, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660131/ http://dx.doi.org/10.1186/1745-6215-16-S2-P217

Ejemplares similares

Adaptive dose-finding designs to identify multiple doses that achieve multiple response targets
por: Bond, Simon, et al.
Publicado: (2013)

Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial
por: Waldron-Lynch, Frank, et al.
Publicado: (2014)

Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study
por: Truman, Lucy A, et al.
Publicado: (2015)

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial
por: Todd, John A., et al.
Publicado: (2016)

Seamless phase IIa/IIb adaptive design with the same primary endpoint for proof of concept and dose finding
por: Yuan, Jiacheng, et al.
Publicado: (2018)

Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities
por: Ezzalfani, Monia, et al.
Publicado: (2013)

Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control
por: Helms, H.-J., et al.
Publicado: (2015)

Importance of achieving the composite endpoints in diabetes
por: Unnikrishnan, Ambika Gopalakrishnan, et al.
Publicado: (2013)

How to design a dose-finding study using the continual reassessment method
por: Wheeler, Graham M., et al.
Publicado: (2019)

Building an adaptive dose simulation framework to aid dose and schedule selection
por: Hooijmaijers, Richard, et al.
Publicado: (2023)

Optimal experimental designs for dose–response studies with continuous endpoints
por: Holland-Letz, Tim, et al.
Publicado: (2014)

phase1RMD: An R package for repeated measures dose-finding designs with novel toxicity and efficacy endpoints
por: Yin, Jun, et al.
Publicado: (2021)

Modeling and Simulation in Clinical Pharmacology and Dose Finding
por: Staab, A, et al.
Publicado: (2013)

SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol
por: Espinasse, Aude, et al.
Publicado: (2023)

Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells
por: Inaba, Akimichi, et al.
Publicado: (2023)

Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial
por: Kojima, Masahiro
Publicado: (2022)

The Use of Genotoxicity Endpoints as Biomarkers of Low Dose Radiation Exposure in Interventional Cardiology
por: Habibi, Martha, et al.
Publicado: (2021)

Model selection and sample size adaptation: HYPAZ trial
por: Bond, Simon, et al.
Publicado: (2011)

CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies
por: Hatayama, Tomoyoshi, et al.
Publicado: (2022)

Prism adaptation and spatial neglect: the need for dose-finding studies
por: Goedert, Kelly M., et al.
Publicado: (2015)

Efforts and achievements in dose reduction at CERN
por: Gobel, K, et al.
Publicado: (1984)

Extended-Interval Gentamicin Dosing for Pulmonic Tularemia
por: Dietrich, Tyson, et al.
Publicado: (2019)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

The influence of interval between doses on response to vaccines
por: Rodrigues, Charlene M.C., et al.
Publicado: (2021)

Low-dose IL-2 reduces IL-21(+) T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes
por: Zhang, Jia-Yuan, et al.
Publicado: (2022)

Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
por: Yap, Christina, et al.
Publicado: (2023)

Erratum: “A Novel Method for the Development of Environmental Public Health Indicators and Benchmark Dose Estimation Using a Health-Based Endpoint for Chlorpyrifos”
por: Zurlinden, Todd J., et al.
Publicado: (2018)

The Dose Response for Sprint Interval Training Interventions May Affect the Time Course of Aerobic Training Adaptations
por: O’Connor, Dominic, et al.
Publicado: (2019)

The Effects of Repeat-Dose Doxorubicin on Cardiovascular Functional Endpoints and Biomarkers in the Telemetry-Equipped Cynomolgus Monkey
por: Engwall, Michael J., et al.
Publicado: (2021)

Interval design to identify the optimal biological dose for immunotherapy
por: Park, Yeonhee
Publicado: (2022)

Impact of time interval and dose rate on cell survival following low-dose fractionated exposures
por: Terashima, Shingo, et al.
Publicado: (2017)

Relationships among achieved heart rate, β-blocker dose and long-term outcomes in patients with heart failure with atrial fibrillation
por: Miller, Robert J H, et al.
Publicado: (2016)

Adaptive evolution influences the infectious dose of MERS-CoV necessary to achieve severe respiratory disease
por: Douglas, Madeline G., et al.
Publicado: (2018)

A product of independent beta probabilities dose escalation design for dual-agent phase I trials
por: Mander, Adrian P, et al.
Publicado: (2015)

Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study
por: Bergenwall, Monique, et al.
Publicado: (2019)

Revisiting dose-finding of monoclonal antibodies in migraine
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Dose response for TCDD promotion of hepatocarcinogenesis in rats initiated with DEN: histologic, biochemical, and cell proliferation endpoints.
por: Maronpot, R R, et al.
Publicado: (1993)

Sweden’s first Take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals
por: Holmén, Elin, et al.
Publicado: (2023)

Dynamics of the QTc interval over a 24‐h dose interval after start of intravenous ciprofloxacin or low‐dose erythromycin administration in ICU patients
por: Berger, Florine A., et al.
Publicado: (2021)

Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population
por: Ross, Ashley L., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_unom36gohavglg0v0bi927l6i0